双特异性T细胞衔接器(CD3×EGFR)三联疗法逆转三代EGFR-TKI耐药NSCLC免疫抑制
本研究针对三代EGFR-TKI耐药NSCLC中约50%缺乏明确耐药机制的难题,通过单细胞RNA测序和多色荧光染色分析耐药后肿瘤微环境变化,并在体外共培养、人源化NOG-EXL小鼠同种移植模型及多组学分析中验证BC3448(EGFR×CD3双特异性T细胞衔接器)、tucidinostat(HDAC抑制剂)与WBP3425(4-1BB激动剂)三联疗法。结果显示三联疗法在奥希替尼耐药模型中肿瘤生长抑制>70%(p<0.001),促进CD8+效应T细胞分化并抑制Tregs和M2巨噬细胞,CD40-CD40L轴激活为TME重塑的关键。
要点
- 三联疗法在奥希替尼耐药模型中肿瘤生长抑制>70%(p<0.001)
- CD40-CD40L轴激活是重塑免疫抑制微环境的关键机制
- 一例免疫治疗耐药患者接受BC3448单药获>2年疾病稳定
核心结论
- 双特异性T细胞衔接器为基础的三联疗法可克服冷肿瘤和免疫抑制性TME对双抗药物的限制,为三代EGFR-TKI耐药提供免疫调节策略。
研究设计与样本
- 对NSCLC患者样本行单细胞RNA测序和多色荧光染色分析耐药后TME变化。
- 采用体外共培养、人源化NOG-EXL小鼠同种细胞源异种移植模型及多组学分析验证三联疗法。
主要发现
- 耐药NSCLC中T细胞浸润或活化减少、免疫抑制性髓系细胞增多。
- BC3448单药体外激活T细胞并诱导肿瘤细胞凋亡,但体内受髓系驱动免疫抑制限制。
- 三联疗法在奥希替尼耐药模型中肿瘤生长抑制>70%(p<0.001),促进CD8+效应T细胞分化并抑制Tregs和M2巨噬细胞。
- CD40-CD40L轴激活为TME重塑关键,空间分析显示CD40L+ T细胞与CD40+巨噬细胞邻近增加,与IFN-γ升高和血管生成减少相关。
- 一例免疫治疗耐药NSCLC患者BC3448单药获>2年疾病稳定。
关键数值与推荐
- 奥希替尼耐药模型中三联疗法肿瘤生长抑制>70%(p<0.001)。
- 耐药NSCLC中约50%病例缺乏精确耐药机制。
临床怎么用
- 提示以双特异性T细胞衔接器联合表观遗传调节和共刺激激动剂的免疫调节策略可能用于三代EGFR-TKI耐药NSCLC。
- CD40-CD40L轴及髓系免疫抑制可作为耐药后TME干预的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acquired resistance to third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) is a major challenge in NSCLC, with approximately 50% of cases lacking precise resistance mechanisms. This study investigates the immunosuppressive tumor microenvironment (TME) driving resistance and develops a novel triple-combination therapy to restore T-cell antitumor activity. METHODS: Single-cell RNA sequencing and multicolor fluorescence staining were performed on NSCLC patient samples to analyze TME changes post-EGFR-TKI resistance. A triple therapy combining BC3448 (EGFR and CD3 bispecific T-cell engager), tucidinostat (histone deacetylase inhibitor), and WBP3425 (4-1BB agonist) was tested using in vitro co-culture assays, syngeneic cell-derived xenograft models in humanized NOG-EXL mice, and multi-omics analyses. RESULTS: Single-cell RNA sequencing revealed reduced T-cell infiltration or activation and increased immunosuppressive myeloid cells in resistant NSCLC. BC3448 monotherapy activated T cells and induced tumor cell apoptosis in vitro but was limited in vivo because of myeloid-driven immunosuppression. The triple therapy significantly enhanced tumor regression in osimertinib-resistant models (tumor growth inhibition >70%, p < 0.001), promoted CD8+ effector T-cell differentiation, and suppressed Tregs and M2 macrophages. CD40-CD40L axis activation between T cells and monocyte-derived macrophages was critical for TME remodeling, with spatial profiling revealing increased CD40L+ T-cell and CD40+ macrophage proximity, correlating with higher IFN-γ and reduced angiogenesis. A durable response to BC3448 monotherapy was observed in an immunotherapy-resistant patient with NSCLC (>2 y of stable disease), presenting a translational potential of this approach. CONCLUSIONS: This study establishes a novel triple therapy that overcomes the limitations of bispecific T-cell engagers in cold and immunosuppressive TMEs and provides an immunomodulatory approach to addressing third-generation EGFR-TKI resistance.
引用
- Guo H, Wang Y, Diao M, et al. Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC. J Thorac Oncol. 2026. PMID: 41672197. doi:10.1016/j.jtho.2026.103607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。